



US007608043B1

(12) **United States Patent**
Lee et al.

(10) **Patent No.:** **US 7,608,043 B1**
(45) **Date of Patent:** ***Oct. 27, 2009**

(54) **OPTICAL AND ULTRASOUND PROBE FOR MONITORING BLOOD VOLUME CHANGES**

(75) Inventors: **Lian-Pin Lee**, Rancho Santa Fe, CA (US); **Jen-Shih Lee**, Rancho Santa Fe, CA (US)

(73) Assignee: **Global Monitors, Inc.**, Rancho Santa Fe, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 665 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **10/849,099**

(22) Filed: **May 19, 2004**

Related U.S. Application Data

(63) Continuation-in-part of application No. 10/274,086, filed on Oct. 18, 2002, now Pat. No. 6,740,036.

(51) **Int. Cl.**
A61B 8/00 (2006.01)
A61B 6/00 (2006.01)
A61B 5/00 (2006.01)

(52) **U.S. Cl.** **600/439; 322/476**

(58) **Field of Classification Search** 600/320, 600/322, 476, 328, 438, 459, 471; 210/739-740, 210/745

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,485,427 B1 * 11/2002 Lee et al. 600/468
6,740,036 B1 * 5/2004 Lee et al. 600/437
2004/0087860 A1 * 5/2004 Lee et al. 600/468

* cited by examiner


Primary Examiner—Francis J. Jaworski

(74) *Attorney, Agent, or Firm*—Jagtiani + Guttag

(57) **ABSTRACT**

An apparatus and method to assess the compressibility, density, and hematocrit of blood including an optical ultrasound probe clipped onto tubing in which blood is flowing. The probe includes a combination of ultrasound transducers, a light emitting diode, and photodiodes. An indicator medium is injected into the bloodstream of the subject over one or more time points. Ultrasound waves are emitted by a transducer and received by another transducer, and a novel signal-processing unit and a computer with a novel computation scheme process the ultrasound signals to assess the phase shift of ultrasound as it transmitted across the blood stream.

20 Claims, 6 Drawing Sheets






Figure 1




Figure 2




Figure 3




Figure 4




Figure 5a




Figure 5b

**OPTICAL AND ULTRASOUND PROBE FOR
MONITORING BLOOD VOLUME CHANGES**

RELATED U.S. APPLICATIONS

This application is a continuation-in-part of U.S. patent application Ser. No. 10/274,086 filed Oct. 18, 2002 and issuing as U.S. Pat. No. 6,740,036 on May 25, 2004, which claims priority to U.S. patent application Ser. No. 09/908,223 filed Jul. 18, 2001 and issuing as U.S. Pat. No. 6,485,427 on Nov. 26, 2002, which claims the priority of U.S. Provisional Application 60/218,906, filed Jul. 18, 2000. All information disclosed in the claimed priority documents are herein incorporated by reference as though recited in full.

FIELD OF THE INVENTION

This invention relates to systems and methods for micro-invasive, continuous monitoring of a patient's changes in blood density and hematocrit in order to determine the blood volume and microvascular pooling of the patient over time to better profile the patient's response to hemodialysis, trauma, or burn injury and to achieve more effective diagnosis and treatment.

BACKGROUND

An apparatus and method are described to monitor the time of sound transmission in the blood stream of a patient, to use a linear relationship between compressibility and density for accurate and sensitive assessment of blood density changes, and to employ optical density for assessment of hematocrit changes due to dilution by saline, dialysate or therapeutic changes. Through appropriate clinical protocols, the density and hematocrit changes are used individually or in combined form to determine the plasma protein concentration, blood volume, change in blood volume, and microvascular pooling of the patient over time.

Hypotension and hypovolemia are common circulatory problems that occur during shock (Chien et al, *American Journal of Physiology*, 210:1411-1418), traumatic injury, dialysis (Amerling et al in *Clinical Dialysis 3rd Edition*, Appleton and Lang editors, 1995) and surgical interventions. A variety of disorders and injuries are related to the occurrence of hypotension (Daugirdas, *Kidney International* 39:233-246). Fluid loss related to burn injury or hemorrhage due to trauma is examples of situations where compensation for such loss is necessary. Infusing isotonic saline, plasma or other physiological solutions into the circulation until arterial pressure is elevated to normal is usually employed as the treatment. Although blood volume reduction correlates with reduction in arterial pressure under laboratory simulations of injury and anesthesia, actual occurrences of traumatic blood loss often show only slightly reduced arterial pressures due to the body's neural compensation mechanisms. Once these mechanisms reach their limits, arterial pressure can drop rapidly. The management of this subnormal arterial pressure is critical to survival; immediate restoration of arterial pressure after traumatic injury can cause more problems than allowing the pressure to remain subnormal. Rapid restoration of arterial pressure results in higher oxygen demand and the increase in blood flow may dislodge clots to cause stroke.

While the body's compensation mechanisms are important to survival, limitations exist in the ability to determine several factors including the volume of blood loss, the distribution of blood volume between the microcirculation and macrocirculation, the necessary volume for infusion, and whether over-

expansion of the blood volume has occurred after infusion. Arterial pressure monitoring is unable to provide sufficient information to address these concerns. A need exists for precise monitoring of changes to blood volume and microvascular pooling in patients, particularly over extended time periods.

Beyond trauma and burn injury, a number of medical conditions require such precise monitoring of blood volume. Invasive surgery and dialysis are two common situations where monitoring blood volume changes provide important information related to the outcome of the surgery and dialysis. For example, about 30% of patients undergoing dialysis in the United States will experience hypotension and, occasionally, circulatory shock. Milder symptoms include muscle cramping and lightheadedness. These dialysis related side effects are implicated in reduced dialysis efficacy.

Dialysis and systems for dialysis are well known in the art. These work by extracting a significant fraction of fluid from the circulating blood. Compensation for this reduction in blood volume normally occurs through fluid restituted from the tissue. The activation of the microcirculation by hemodialysis leads to pooling of blood in the microcirculation affecting a low venous return, poor cardiac filling, lowered cardiac output and then hypotension. For patients undergoing a well-controlled fluid removal, these cardiovascular changes and hypovolemia are the reason for hypotension development during the course of hemodialysis. Using saline or dialysate dilution, we can monitor the change in blood volume over times, for example every half hour. A continuous change in blood density can be analyzed and microvascular pooling within the circulation can be determined. These parameters can be used by physicians to carefully monitor the cardiovascular changes that are responsible for the development of hypotension in dialysis patients.

When patients undergo hemodialysis or are subject to trauma or burns, there is significant exchange of fluid and protein between the tissue and blood compartment. These exchanges will alter the plasma protein concentration. Consequently an on-line system capable of monitoring changes in plasma protein concentration will be valuable to the physician in selecting an appropriate fluid therapy to compensate for the loss of plasma and/or plasma protein. Currently no system can assess on-line and clinically monitor plasma protein concentration.

The use of sound velocity measurements in blood to assess blood volume has been attempted and described previously. Krivitski, in U.S. Pat. Nos. 5,453,576 and 5,685,989 describes an apparatus and method for measuring several hemodynamic parameters by using a sound velocity sensor. The information contained in the '576 and the '989 patent is incorporated by reference as though cited in its entirety. The technique described uses a linear approximation of a non-linear relationship between the sound velocity and the density of the blood. This approximation introduces additional error into the volume computation, which limits the accuracy of the system. Further, the '576 patent is limited to large variations in sound velocity which make it inaccurate to assess blood volume.

The system patented by Schneditz in U.S. Pat. No. 5,830,365 also utilizes sound velocity for the measurement of total protein concentration, and then the blood volume by altering the dialyzer to run at a different ultrafiltrate extraction rate. These two methods are limited to large variations in sound velocity and the requirement of no blood pooling to the microcirculation.

Several other devices exist which are used to monitor blood volume or blood parameter changes. These include the

Know-Recirc™ hematocrit measurement device produced by H&H Control Systems (Jackson, M S) and described in U.S. Pat. No. 5,312,550 and an optical device marketed under the Crit-Line® platform and the Transcutaneous Access Flow device by HemaMetrics Corporation (Boston, Mass.) described in U.S. Pat. Nos. 5,499,627 and 6,117,099. These devices continuously monitor the change in hematocrit over a dialysis session. Increases in hematocrit over the session are interpreted as a decrease in plasma volume thereby theoretically providing a mechanism for monitoring blood volume changes. This method does not account for the Fahraeus effect where microvascular pooling of blood can result in an increase in hematocrit. By not correcting for microvascular pooling, blood volume changes estimated by this device are off by a factor of two or more. Again, sensitivity of this device is limited and can cause incorrect diagnoses or treatments. Daugirdas (*American J. Kidney Disease*, 38:S11-S17, 2001) commented that none of these hematocrit approaches are successful because the conclusion from the measured hematocrits exhibits considerable interpatient and inpatient variability. A similar problem exists in the work of Polaschegg in U.S. Pat. No. 5,230,341. Correction for microvascular pooling and sensitivity are deficient in the '341 patent and incorrect results on the projected blood volume occur leading to potentially harmful treatments.

SUMMARY OF THE INVENTION

The present invention provides a method and an optical/ultrasound probe to accurately and reliably determine compressibility, density, hematocrit, and plasma protein concentration, and the changes of these blood parameters due to the infusion of saline or dialysate for the quantification of blood volume or microvascular pooling in patients. The invention utilizes the changes of blood density and hematocrit over time while accounting for the effect of the microcirculation to provide medical professionals with valuable information on microvascular pooling and hypovolemia for the prevention of complications related to trauma and hemodialysis.

Further, the present invention measures through the ultrasound probe and a signal processing unit the phase shift between emitting ultrasound and receiving ultrasound, converts the phase shift to transmission time and subsequently to sound velocity of blood flowing in a corporeal or extracorporeal system, and uses the linear relationship between compressibility and density to calculate from sound velocity the compressibility and density of blood.

The novel embodiments of the optical ultrasound probe provide significant advantages over the prior art. These include:

- (1) A simpler hardware and software to detect phase shift of ultrasound signals for the determination of sound velocity;
- (2) A factory procedure to calibrate the relationship between the sound velocity and density of blood on using the ultrasound probe to determine density;
- (3) A set of computer files and equations to account for the dependence of density and sound velocity of blood on temperature;
- (4) An on-line method using the ultrasound probe to calibrate the optical density of the optical probe for the determination of hematocrit;
- (5) The combined use of the hematocrit and density measurement for the determination of plasma protein concentration;
- (6) A data averaging procedure to better define the time course of density, hematocrit, and plasma protein con-

centration and to better characterize the interrelation between hematocrit and density changes;

- (7) A graphic organization of the hematocrit and density measurements to differentiate whether a therapeutic process induces the patient to produce hypovolemia, microvascular pooling or both;

- (8) An on-line analysis and procedure to quantify the time course of microvascular pooling, blood volume, and plasma protein concentration.

The combination of these eight features enables the optical/ultrasound probe to be produced at low cost, to achieve accurate assessments and to provide crucial information for the physician to select an effective strategy to prevent or treat hypertension in any patient.

Blood is a mixture of cells and plasma. The density and compressibility of blood is the sum of its components weighted by the volume fraction. The velocity of ultrasound in blood is related to a variety of factors, including the hematocrit, blood and plasma density, plasma protein concentration, and total protein concentration of blood. Likewise, blood compressibility also relates to these physical parameters of blood and plasma. These relationships are difficult to identify because of a lack of accurate measurement systems.

Attempts at relating variable factors have deduced approximations to be utilized by the system described in the '576 patent and in the Know-Recirc™ and the Crit-Line® hematocrit measurement system. These empirical approximations limit the accuracy of the measurement systems and introduce errors into the data analysis.

The more accurate calculation of blood volume and the determination of its distributions within the circulation taught herein are used to monitor and treat patients more effectively. Software and hardware are configured to generate and receive the ultrasound wave and light and use the information to monitor the changes in plasma protein concentration and redistribution of blood volume in patients. Methods for interfacing the data generated by the monitoring technique on the transmission of sound, absorption and reflection of light with analytical machinery will become apparent to those of skill in the art based on the description contained herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic drawing of an embodiment of the optical ultrasound probe. It has a pair of ultrasound transducers, a light emitting diode and two photodiodes, and a thermistor. The probe is clipped on to a tube with flowing blood. In this design, the transducers, diodes and thermistor have no direct contact with the blood.

FIG. 2 is an illustration identifying the phase and time shift of the receiving ultrasound from the emitting ultrasound. The signal processing unit will first assess the relative phase shift of the sound waves and then through a factory calibration procedure to obtain the overall phase shift, which is used to compute the sound velocity, compressibility and finally density of blood.

FIG. 3 is a schematic drawing of the optical ultrasound probe as it is used to measure compressibility, density and hematocrit of blood flowing through the tubing of an extracorporeal system connected to the patient.

FIG. 4 is a density hematocrit plot when blood in a corporeal circuit is diluted by plasma or saline. The density and hematocrit are measured by the optical ultrasound probe.

FIG. 5a is a density hematocrit plot following the injection of a saline bolus into the extracorporeal circuit of a hemodialysis machine. The injection was made at the arterial port of

the hemodialysis circuit and the density and hematocrit were measured with the probe placement at the venous site of the hemodialysis circuit, which was downstream of the dialyzer.

FIG. 5b is the same data of FIG. 5a but with advancement in time for hematocrit.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

FIG. 1 shows an embodiment of the ultrasound optical probe. In this embodiment, the probe exists in a clip 26, which is mounted with the ultrasound emitting transducer 22, the receiving transducer 24, the light-emitting diode 62, the photodiode 64 for reflectance measurement, and the photodiode 66 for absorbance measurement. The surfaces of the transducers 22 and 24 and diodes 62, 64 and 66 are directly in contact with a tubing 14 inserted into the clip 26. The tubing 14 is connected to an extracorporeal circuit from which the flowing fluid (blood, plasma or saline) is used for the measurement.

Cabling and connectors 20 transmit power from a signal generator within the ultrasound signal-processing unit 54 to activate the emitting transducer 22 into producing a continuous wave of ultrasound at a frequency of about 3 to 5 Megahertz. The power signal is digitized as the excitation signal by one channel of a dual channel analog-to-digital (A/D) converter within the ultrasound signal-processing unit 54, which is shown in FIG. 3. The receiving transducer 24 receives the ultrasound wave produced by emitting transducer 22 and sends it to the other channel of the dual channel A/D converter for digitization. Both the digitized excitation and receiving signals are sent via cable 74 to the computer 58 shown in FIG. 3 for the determination of the phase shift of the receiving signal from the excitation signal.

In this embodiment, the clip 26 has a gap about 5 mm for the insertion of the tubing 14 whose outside diameter is about 6.2 mm. Tubing with a diameter other than 6.2 mm can be used in the system and the dimensioning adjustments to the clip will be obvious to those skilled in the art. The adjustment will be incorporated through the parameters stored in a data file accompanying the probe. Ultrasound gel is used to facilitate the insertion of the tubing 14 into the clip and to provide an airtight contact between the tubing 14 and the transducers 22, 24, preventing errors that can be caused by the reflection of ultrasound through air bubbles likely trapped between the transducers and tubing.

A power source within an optical signal-processing unit 70 sends a driving power through cable 72 to activate the photodiode 62 to emit light with a wavelength of 805 nm. The signals from the photodiodes 64 and 66 are then digitized by a dual channel A/D converter within the optical signal-processing unit 70 and are sent to computer 58 for the determination of the optical density and subsequently, through the equations discussed herein, the change in hematocrit of the blood flowing in the tubing 14. A thermistor 28 measures the temperature of flowing blood. The entire optical ultrasound probe 26 is housed in an insulator to assure the temperature at the thermistor 28 is identical to that of the flowing blood.

The information obtained by the ultrasound transducers is sent through the ultrasound signal-processing unit to a computer, which incorporates a new computation scheme and a novel linear relationship between compressibility and density to carry out the computation from the measurement of phase shift of blood. The following linear relationship, deduced from the fact that blood is a mixture of protein and ultrafil-

trate, describes the dependence of the compressibility (κ) on the density (ρ) by a slope (b) and an x-intercept (a) as in Equation 1.

$$\kappa = a + b\rho \quad \text{Equation 1}$$

This relationship holds over a wide range of hematocrit, plasma protein concentration, and total protein concentration of blood, blood density, and plasma density. The propagation velocity of ultrasound c and the density in blood are related to compressibility as shown in Equation 2.

$$\kappa = \rho/c^2 \quad \text{Equation 2}$$

We can combine Equation 1 and 2 to obtain a quadratic equation for solving the density and compressibility from the measured sound velocity. Tests with the ultrasound transducer system described herein and a system that measures directly the density demonstrate that the density and sound velocity are related by the quadratic equation so derived.

The ultrasound signal-processing unit sends out a signal to excite a transducer to emit ultrasound at a frequency (f) of 3 to 5 Megahertz. After the transmission of the ultrasound through the tube wall and blood medium, a receiving transducer picks up the ultrasound. The hardware employed in the ultrasound signal-processing unit has a dual channel A/D converter to convert the excitation signal and receiving signal to digitalized forms at a sampling frequency of 65 or 105 mega samples per second (MSPS). These samples, identified respectively as E_i and R_i , with i being the sampling index, are stored on the computer. After a period of time, the sampled data are multiplied and summed according to the computation scheme defined by Equations 3 and 4:

$$M_1 = \sum(E_i R_i) \text{ with the summation from } i=1 \text{ to } N \quad \text{Equation 3}$$

$$M_2 = \sum(E_{i+j} R_i) \text{ with the same summation as above} \quad \text{Equation 4}$$

where j is chosen to shift the phase of the emitting signal by 90 degrees in accordance with the frequency of excitation and sampling frequency. The total number N used for the summation is chosen to be an integer multiple of 4j to cover $N/(4j)$ cycles of the ultrasound. Then we determine the phase shift of the receiving signal from the emitting signal as:

$$\phi = \tan^{-1}(M_2/M_1) \quad \text{Equation 5}$$

where ϕ is expressed in the unit of degree.

FIG. 2 shows the time and phase shift between the emitting ultrasound and receiving ultrasound. With the use of continuous wave, the time of each oscillation (T_o) is $1/f$ and the relative time shift of the receiving signal from the emitting one (T_{shift}) is $\phi/(f \cdot 360^\circ)$. However, the peak-to-peak time shift of the receiving signal from the excitation signal has an offset (an integer number n of ultrasound oscillations) from the phase shift of Equation 5. This offset is equivalent to adding $n \cdot 360^\circ$ to the phase shift ϕ .

Let the phase shift and sound velocity of saline, hypertonic saline, and blood be identified as ϕ_s , c_s , ϕ_h , c_h , ϕ_b and c_b respectively. The time for the ultrasound to transmit from the emitting transducer to the receiving one relates for each medium to its phase shift by these equations:

$$\phi_s + n \cdot 360^\circ = f \cdot 360^\circ \cdot (L/c_s + 2h/c_w) \quad \text{Equation 6}$$

$$\phi_h + n \cdot 360^\circ = f \cdot 360^\circ \cdot (L/c_h + 2h/c_w) \quad \text{Equation 7}$$

$$\phi_b + n \cdot 360^\circ = f \cdot 360^\circ \cdot (L/c_b + 2h/c_w) \quad \text{Equation 8}$$

where h is the wall thickness of the tube inserted into the trough of the HDM probe, $L+2h$ is the distance between the

transducers, and c_w is the sound velocity of the tube wall. Subtracting these equations to eliminate c_w and solving for the sound velocity of blood, we have

$$c_s/c_b = 1 - (1 - c_s/c_h)(\phi_b - \phi_s)/(\phi_h - \phi_s) \quad \text{Equation 9}$$

The use of this velocity ratio in the following quadratic equation solves the blood density:

$$1 - (c_s/c_b)^2 = (b-1)(\rho_b/\rho_s - 1) + b(\rho_b/\rho_s - 1)^2 \quad \text{Equation 10}$$

To obtain a more explicit equation relating the density and phase shift, we will reference our measurement to that of a whole blood, which has a density of 1045 g/l at 37° C. Generated from Equation 9 and the linearized version of Equation 10 around the reference blood density (ρ_{ref}), we can determine the blood density (ρ_b) by Equation 11.

$$\rho_b = \rho_{ref} + \rho_s G (\phi_b - \phi_{ref}) / (\phi_h - \phi_s) \quad \text{Equation 11}$$

where ϕ_{ref} is the phase shift of the reference blood and the constant G is given by Equation 12.

$$G = 2(c_s/c_{ref})(1 - c_s/c_h) / [(b-1) + 2b(\rho_{ref} - \rho_s)/\rho_s] \quad \text{Equation 12}$$

To determine the integer n in Equations 6 to 8, we will measure the change in phase $\Delta\phi_s$ following a small increment in the ultrasound frequency by Δf . The application of Equation 6 to this scenario yields Equation 13 to relate the phase and frequency change.

$$\Delta\phi_s = \Delta f 360^\circ (L/c_s + 2h/c_w) \quad \text{Equation 13}$$

After the division of Equation 13 by Equation 6, we reorganize the result to Equation 14 for the determination of n.

$$n = \text{Round}[(f\Delta\phi_s/\Delta f - \phi_s)/360^\circ] \quad \text{Equation 14}$$

where the function "Round" stands for the rounding of number in [] to its nearest integer.

The parameters in Equations 9 to 12 are dependent on the temperature. The dependence of G on the temperature can be approximated by Equation 15.

$$G = G_0 [1 - G_1 (T - 37^\circ \text{ C.})] \quad \text{Equation 15}$$

For the isotonic and hypertonic saline employed in the calibration and the blood chosen as the reference, the constant G_0 is about 0.06 and the constant G_1 is about 0.0033. The factory will pre-calibrate a given probe and include in the data file the value of n and the temperature dependence of ϕ_s , ϕ_{ref} , $\phi_h - \phi_s$, ρ_s and ρ_{ref} . The computation scheme and the ultrasound signal processing unit of the present invention can be incorporated with the compressibility probe described in U.S. patent application Ser. No. 09/908,223 filed Jul. 18, 2001, to which the present application claims priority, to improve the functionalities of the compressibility probe to determine fluid density.

In general the data file will contain data to cover a wide spectrum of tubing that is used in hemodialysis machines of various manufacturers. When the optical ultrasound probe is in research or clinical uses, the computer will employ the probe and its signal processing unit to determine the phase shift (ϕ_b) of ultrasound transmission through the blood flowing in the tubing and the thermistor will report the temperature of blood. Then the computer will pick the factory data file for the hemodialysis machine in use, temperature, and phase measurement to determine from Equation 11 the approximate value of blood density or from Equation 9 and 10 the blood density.

When the blood is mixed with a fluid of density ρ_r and no red blood cells, the dilution of the density and hematocrit of blood follows Equation 16.

$$(\rho_b - \rho_r) = [(\rho_{b,1} - \rho_r)/H_1]H \quad \text{Equation 16}$$

where $\rho_{b,1}$ is the blood density and H_1 is the hematocrit before dilution. The in vitro results performed on a corporeal circuit for saline and plasma dilution are illustrated in FIG. 4.

Right after the connection of the optical ultrasound probe to the hemodialysis circuit and the initiation of the dialysis, the first half hour will be used for the temperature of blood circulating through the circuit and the probe to reach equilibrium. Then a 5 ml of isotonic saline is injected into the arterial port of the circuit and the changes in density are measured through the ultrasound probe, its signal processing unit and the computer. The optical probe measures the absorbance of light as it transmitted through the blood or the reflectance of light as the light is reflected from the blood. These measurements are expressed as optical density (OD). By plotting the change in optical density ΔOD against that of density $\Delta\rho_b$, we can obtain the slope b_2 in the linear relationship of Equation 17:

$$\Delta\rho_b = b_2 \Delta OD \quad \text{Equation 17}$$

Its combination with Equation 16 for saline dilution yields Equation 18:

$$\Delta H/H_1 = [b_2/(\rho_{b,1} - \rho_r)] \Delta OD \quad \text{Equation 18}$$

In practice, the optical probe is located downstream of the ultrasound probe. To carry out the data analysis we will advance the optical signal by a time for which the linear fit between the optical density and density has the correlation coefficient closest to unity. Then the slope of this linear fit is taken as b_2 . An example of the density plot before the time adjustment is depicted in FIG. 5a and that after the time adjustment is depicted in FIG. 5b. For later measurements, Equation 18 and the slope are used to determine the change in the hematocrit ratio ($\Delta H/H_1$) from the change in measured optical density.

Density dilution methods are well known methods for blood volume determination. A volume of isotonic saline at approximately two to three percent of the total blood volume is infused into the circulation. The saline density is lower than the blood density and mixing of the saline with the circulating blood leads to a reduction in blood density. Where ρ_1 and ρ_2 are the density of the blood prior to and after the infusion of isotonic saline, ρ_s is the density of saline and ΔV is the increase in total blood volume due to the saline infusion. A relationship exists between these densities and the total blood volume (V_b) of the patient. This relationship is shown in Equation 19.

$$V_b = A[\Delta V(\rho_2 - \rho_s)/(\rho_1 - \rho_2)] \quad \text{Equation 19}$$

The constant A varies slightly by species and accounts for the Fahraeus effect in the microcirculation. The constant A is approximately equal to 1.14 for human and rabbit and can be determined for any animal. The dilution can be repeated over time, for example every hour, to assess the temporal change in blood volume.

Once the density and hematocrit of the patient are recorded over time, the data will be fitted by polynomial functions of the time to obtain the time course of the density (ρ_b) and that of the hematocrit (H). Then the plasma density ρ_p is calculated by:

$$\rho p l = (\rho_b - \rho_{rbc}H)/(1-H) \quad \text{Equation 20}$$

where ρ_{rbc} is the density of red blood cells. Finally the plasma protein concentration (C_{pl}) is calculated as:

$$C_{pl} = (\rho_{pl} - \rho_p)/0.264 \quad \text{Equation 21}$$

The unit of this plasma protein concentration is in grams of protein per liter of plasma. Expressing through the change in hematocrit and that in density, the change in plasma density is given by Equation 22.

$$\Delta\rho_{pl}=\Delta\rho_b/(1-H)-(\rho_{bc}-\rho_b)\Delta H/(1-H)^2 \quad \text{Equation 22}$$

Equation 16 specifies that the dilution of blood by a fluid with a density ρ_f , will have in a hematocrit density plot a slope of $(\rho_{b,1}-\rho_f)/H_1$. The particular result of FIG. 5b provides a slope characterizing the process of saline dilution. If the subsequent measurements yield a density hematocrit plot with a slope smaller than that in FIG. 5b, we may conclude that the blood is diluted with a fluid density larger than that saline. (The fluid density relates to saline density and protein concentration of the fluid through Equation 21.)

There are two clinical protocols that the physician can use to assess blood volume, change in blood volume, and microvascular pooling. First clinical protocol prescribes the performance of one blood volume measurement at the beginning of the hemodialysis session and another at the end of the session. These two measurements determine the change in blood volume (ΔV_b). In the time between these two measurements, the compressibility probe monitors the blood density and the dialysis machine will report the ultrafiltrate removed from the patient as $\Delta V_{dialysis}$. If the blood density right after the first blood volume measurement is defined as ρ_4 and the blood density before the second blood volume measurement is defined as ρ_5 , the corresponding hematocrits are H_4 and H_5 . Then the pooling of the blood to the microcirculation can be calculated from Equation 23.

$$\frac{\Delta V_{pooling}}{\Delta V_b} = B \left\{ V_b (\rho_4 - \rho_5) F_{cell} (\rho_4 - \rho_{pl}) + (\Delta V_{dialysis} - 2\Delta V_b) [(1-H_4)/(1-F_{cell}H_4)] (\rho_{pl} - \rho_5) / [3(\rho_4 - \rho_{pl})] - \Delta V_b \right\} \quad \text{Equation 23}$$

where ρ_{pl} is the density of plasma right after the first blood volume measurement and ρ_5 is the density of the ultrafiltrate or saline, the constant F_{cell} is 0.87, the constant B is 2.78. The amount of pooling is indicative of how the patient is susceptible to microvascular pooling.

The second clinical protocol uses the time course of the measured density and hematocrit to determine the slope of the hematocrit density plot, the change in total blood volume (ΔV_b) and the volume pooled to the microcirculation ($\Delta V_{pooling}$). In reference to the initial density and hematocrit right after temperature equilibrium, the change in blood density, hematocrit and plasma density from their initial value is identified as $\Delta\rho_b$, ΔH , and $\Delta\rho_{pl}$ respectively. ΔV_b and $\Delta V_{pooling}$ are to be calculated by Equation 24 and 25:

$$\frac{\Delta V_b/V_b = (\frac{3}{2})[\Delta\rho_{pl}/(\rho_{pl}-\rho_5)](1-F_{cell}H)^{-1/2}(\Delta V_{dialysis}/V_b)}{V_b} \quad \text{Equation 24}$$

$$\Delta V_{pooling}/V_b = 3.46 \{ F_{cell} \Delta H / H - [(1-H)/H] \Delta V_b / V_b \} \quad \text{Equation 25}$$

The change in the blood volume of macrocirculation is now determined by Equation 26:

$$\Delta V_{macro}/V_b = \Delta V_b - \Delta V_{pooling} \quad \text{Equation 26}$$

This change serves as an index on how well cardiac filling is accomplished while the slope of the hematocrit density plot serves as an index on the exchange of fluid and protein between the tissue and blood compartment.

There are several working models of the ultrasound system to assess blood density. In one signal processing embodiment the transducer 16 is activated by any commercially available pulser/receiver, including a Panametrics 5072PR pulser/receiver, to emit ultrasound impulses of about 15 to 20 Megahertz at a rate of about 100 Hertz. After its transmission

through the flowing blood, the second transducer 18 receives the ultrasound signal. The trigger signal from the pulser/receiver triggers a digital oscilloscope such as a LeCroy 9350AL oscilloscope or a Synatec A/D converter to sample the signal from the receiver 18 at 100 Megahertz to 1 Gigahertz. Cabling and connectors 20 are shown to connect the transducers 16 and 18 to the electronic devices. The digitized samples so triggered are transferred to a computer for the determination of the phase shift and the calculation of sound velocity using the equations described herein. In another embodiment, the signals from the receiving transducer and the function generator to excite the emitting transducer are processed by a Phase Lock Amplifier such as Stanford Research System SR 844, to obtain the phase shift. Through a calibration of the shift as a function of density, the system can then be used to assess blood density.

In a preferred embodiment, the optical ultrasound probe system is constructed with a novel ultrasound signal processing unit, a simple computation scheme, and a two-media calibration procedure that are specifically designed to process the ultrasound signals for phase shift and subsequently density determination. In one design, a dual channel A/D converter is used to sample the data at 65 MSPS and an ultrasound at the frequency of 5.417 Megahertz. The digitized data are multiplied and summed in accordance with Equations 3, 4 and 5 for the determination of the phase shift. For this case, the value of j used in Equation 4 is 3. (If a frequency of 3.25 or 4.063 Megahertz is used, the value of j will be 5 or 4 respectively.) When A/D converters having a sampling rate of 105 MSPS are used in another design, an ultrasound frequency of 5.25 Megahertz and a value of 5 for the j in Equation 4 will be used. (Similarly the use of a frequency 3.281, 3.75, or 4.375 Megahertz will have a value of 8, 7 or 6 for j respectively.) After the signal processing to determine the phase shift, the use of Equation 11 and the data file from the factory allows the computer to determine the blood density. Working together with the optical probe, the measurement of density and hematocrit can now be used to determine plasma protein concentration. One can also determine from the change in density and hematocrit the blood volume, change in blood volume, and blood volume pooled to the microcirculation.

Conventionally, the 90-degree shift of the excitation signal in Equation 4 is accomplished by electronic means. The above digitized scheme and the frequency selected for sampling and excitation allow us to accomplish the 90-degree shift of the excitation signal by simply changing the index used in the summation processing of Equation 4. This data manipulation simplifies the electronics of the ultrasound signal-processing unit considerably. The processing unit and the computer process ultrasound signals of 3 to 5 Megahertz to achieve a resolution in time shift of the order of 0.05 nanosecond.

An excitation signal is generated by the signal generator in the ultrasound signal-processing unit 54 as shown in FIG. 3 that is identical to the ultrasound wave 30 emitted by the transducer of FIG. 2. A second signal is transmitted by the receiving transducer 24 as it receives the ultrasound wave, which has been transmitted through the wall of the tube 14 and blood. The ultrasound signal-processing unit 54 and the computer 58 process the excitation and receiving signal for the determination of the phase shift of the two signals. The division of the phase shift by $f:360^\circ$ is the time shift T_{shift} between the excitation and received signals shown in FIG. 2. For the purpose of illustration, the ultrasound peak 34 is transmitted to become the peak 36. The overall time delay (i.e. peak to peak time shift) on ultrasound transmission is the

sum of the time shift (T_{shift}) and a multiple of ultrasound period (nT_0). After this adjustment of phase shift, it is processed through Equation 9 to determine the sound velocity, then Equation 10 the density and finally Equation 2 the compressibility. One can also obtain an approximate density through Equation 11.

The integration of the clip-on ultrasound optical probe with an extracorporeal dialysis system to form an extracorporeal blood treatment device is shown schematically in FIG. 3. The dialysis system preferably includes a pump, a bubble trap, and a hemodialysis filter. The dialysis system **48** is preferably located upstream of said optical probe **26** as shown in FIG. 3. In practice, tubing **14** includes an arterial segment and a venous segment, first tubing branch **14a** and second tubing branch **14b** respectively. First tubing branch **14a** leads from a blood vessel of a patient to dialysis system **48**. As shown in FIG. 3, the blood vessel is an artery **40**. A portion of the blood **46** flowing through the artery **40** is drawn into the first tubing branch **14a** which has a low blood pressure for delivery first through the dialysis system **48**. After ultrafiltration by the dialysis system, blood **46** then continues its flow through the clip-on ultrasound optical probe **26** via second tubing branch **14b** which has high blood pressure.

An infusion system comprising a saline bag **44** containing a fixed amount of saline is connected to tubing **14** along first tubing branch **14a**. Normally, a hemostat **50** clamps up the tubing connecting the saline bag to the tubing **14**. For the infusion of saline into the blood circulation, the release of hemostat **50** and the low blood pressure in first tubing branch **14a** allows the dialysis system **48** to withdraw the saline in bag **44** into the extracorporeal blood treatment device. The upstream location of the infusion system relative to the dialysis system **48** allows this automatic withdrawal of indicator fluid for infusion into said blood system once the clamping hemostat **50** is open. The bag **44** is prepackaged with 50, 100, 150 or 200 ml of saline, which is selected according to the body weight of the patient. The connection to bag **44** will be re-clamped by the hemostat after the completion of infusion within about one-half minute. The saline-enriched blood **12** is returned to the patient's circulation via second tubing branch **14b** through the connection to a blood vessel, such as the illustrated vein **42**.

Optical probe **26** is attached to tubing **14** of the extracorporeal blood treatment device along second tubing branch **14b** downstream from dialysis system **48**. The high blood pressure in second tubing branch **14b** assures good tubing contact with the surface of the transducers **22** and **24** of optical probe **26**, which subsequently assures that a good signal is received by transducer **24**. The transducers **22** and **24** in the clip-on probe **26** respectively emit and receive the ultrasound waves through blood **46**, which are passed via cabling **20** to the ultrasound signal-processing unit **54**.

The digitized information is relayed via cabling **56** to the computer **58** where overall transmission time, sound velocity, compressibility and density are continuously computed. The diode **62** in the clip-on probe **26** emits light and diodes **64** and **66** receive absorbed or reflected light. Delivered via the optical signal-processing unit **70** through cable **74**, the optical density is used by computer **58** for the determination of hematocrit. The temperature signal from the thermistor **28** is directly transmitted to the computer **58**. The temperature is used to correct the density assessment to the same temperature for the computation of the density change produced by a saline dilution procedure or by the patient's response to treatment. Temperature is incorporated in the calculations using the equations described herein.

Additional embodiments of the clip-on ultrasound optical probe will become apparent to those of ordinary skill in the art.

What is claimed is:

1. A system for monitoring changes in blood volume and microvascular pooling in animals, comprising:
 - an extracorporeal blood treatment device comprising tubing having a first branch and second branch and a dialysis system, said first tubing branch conducting blood from an arterial segment of said blood system to said dialysis system, and said second tubing branch conducting blood from said dialysis system to a venous segment of said blood system;
 - a diagnostic apparatus attached to said tubing of said extracorporeal blood treatment system wherein said diagnostic apparatus emits and receives an ultrasound wave and a light wave through blood flowing through said extracorporeal system;
 - a signal processing system, wherein said signal processing system initiates and records ultrasound waves and light transmissions, determines phase shift between emitting and receiving ultrasound waves, monitors with high resolution sound velocity, density, compressibility, and optical density of blood, hematocrit, and plasma protein concentration, and assesses changes in said sound velocity, density, compressibility, optical density, hematocrit, and plasma protein concentration of modified blood at an equivalent temperature;
 - an infusion system, said infusion system containing a known amount of an indicator fluid, said indicator fluid being infused into said blood system at an infusion connection located upstream of said dialysis system and diagnostic apparatus, wherein infusion of said indicator fluid into said blood system changes the density of said blood system as measured through said diagnostic apparatus and said signal processing system;
 - a calibration system, said system including said signal processing system and a factory pre-calibrated probe; and
 - a computing system for determining blood volume, changes in blood volume, changes in plasma protein concentration, and microvascular pooling from said hematocrit and density change.
2. The system of claim 1 wherein said signal processing system includes an ultrasound signal processing unit, an optical signal processing unit, an ultrasound and light generator, and two dual channel A/D converters.
3. The system of claim 2, wherein said calibration system employs data from said factory pre-calibrated probe on two fluids of known sound velocity to determine the relationship between the phase shift generated by said signal processing system and the sound velocity of blood for the assessment of compressibility and density of blood.
4. The system of claim 2, wherein said calibration system employs data from said factory pre-calibrated probe on a saline injection process to match the optical density measured by said optical processing unit with the density measurements made by said ultrasound signal processing unit to calibrate optical density in terms of hematocrit.
5. The system of claim 2 wherein said ultrasound wave is processed by said signal-processing system and said computer system using a novel computation scheme to determine the phase shift between emitting and receiving ultrasound.
6. The system of claim 1 wherein said human system is adapted to monitor blood changes in a human.
7. The system of claim 1 wherein said diagnostic apparatus is a clip-on probe having mounted thereon at least one ultra-

13

sound emitting transducer, at least one ultrasound receiving transducer, at least one light emitting diode, and at least two photodiodes.

8. The system of claim 7 wherein said at least one ultrasound emitting transducer, said at least one ultrasound receiving transducer, said at least one light emitting diode, and said at least two photodiodes are tightly clipped onto said tubing of said extracorporeal blood treatment device for transmission of ultrasound and light.

9. The system of claim 7 wherein said diagnostic apparatus further comprises a thermistor, wherein said thermistor takes a temperature measurement that is incorporated into a computation to convert measured sound velocity to density of blood.

10. The system of claim 1 wherein said indicator fluid is isotonic saline or dialysate.

11. The system of claim 1 wherein said dialysis unit is located upstream of said diagnostic apparatus.

12. A system for monitoring changes in blood volume and microvascular pooling in animals, comprising:

a diagnostic apparatus attached to an extracorporeal blood treatment device, said diagnostic apparatus emitting and receiving an ultrasound wave and a light wave through blood flowing through said blood treatment device, said blood treatment device being adapted to connect an artery and a vein of said animal;

a signal processing system, wherein said signal processing system determines a phase shift between said emitting and receiving ultrasound wave, and determines absorbance and reflectance of said light wave;

at least two control units within said signal processing system for detecting compressibility, density, hematocrit and plasma protein concentration with high resolution, for assessing changes in said compressibility, density, hematocrit, and plasma protein concentration at an equivalent temperature, for initiating and recording ultrasound and light waves, and for monitoring physical parameters of modified blood; and

a computer memory unit for determining blood volume and microvascular pooling from said hematocrit and density change.

13. The system of claim 12 wherein said system is adapted to monitor blood changes in a human.

14. The system of claim 12 wherein said diagnostic apparatus is a clip-on probe having mounted thereon at least one ultrasound emitting transducer, at least one ultrasound receiving transducer, at least one light emitting diode, and at least two photodiodes.

15. The system of claim 12 further comprising a thermistor attached to said diagnostic apparatus.

16. The system of claim 12 further comprising an infusion device for diluting said blood via a dilution procedure wherein a known volume of said saline or dialysate is infused into said blood system for use in computing blood volume of the animal.

14

17. A method for monitoring changes in blood volume and microvascular pooling in animals, comprising:

conducting blood from a blood system to an extracorporeal blood treatment device and back into said blood system, said extracorporeal blood treatment device comprising tubing having a first branch and second branch and a dialysis system, said first tubing branch conducting blood from an arterial segment of said blood system to said dialysis system, and said second tubing branch conducting blood from said dialysis system to a venous segment of said blood system;

emitting and receiving an ultrasound wave and a light wave through blood flowing through said extracorporeal blood treatment device via a diagnostic apparatus attached to said tubing of said extracorporeal blood treatment device;

initiating and recording ultrasound waves and light transmissions; determining phase shift between emitting and receiving ultrasound waves; monitoring with high resolution sound velocity, density, compressibility, and optical density of blood, hematocrit, and plasma protein concentration; and assessing changes in said sound velocity, density, compressibility, optical density, hematocrit, and plasma protein concentration of modified blood at an equivalent temperature via a signal processing system;

infusing an indicator fluid into said blood from said blood system via an infusion system connected to said extracorporeal blood treatment device, said infusion system containing a known amount of an indicator fluid, said indicator fluid being infused into said blood system at an infusion connection located upstream of said dialysis system and said diagnostic apparatus, wherein infusion of said indicator fluid into said blood system changes the density of said blood system as measured through said diagnostic apparatus and said signal processing system; calibrating phase shift as a function of density; and determining blood volume, changes in blood volume, changes in plasma protein concentration, and microvascular pooling from said hematocrit and density change via a computing system.

18. The method of claim 17 further comprising taking a temperature measurement of said blood via a thermistor and incorporating said temperature measurement into a computation to convert measured sound velocity to density of blood.

19. The method of claim 17 wherein said indicator fluid is isotonic saline or dialysate.

20. The method of claim 17 wherein said ultrasound wave is processed by said signal-processing system and said computer system using a computation scheme to determine the phase shift between emitting and receiving ultrasound.

* * * * *

专利名称(译)	用于监测血容量变化的光学和超声探头		
公开(公告)号	US7608043	公开(公告)日	2009-10-27
申请号	US10/849099	申请日	2004-05-19
[标]申请(专利权)人(译)	全球语言监测		
申请(专利权)人(译)	全球语言监测, INC.		
当前申请(专利权)人(译)	全球语言监测, INC.		
[标]发明人	LEE LIAN PIN LEE JEN SHIH		
发明人	LEE, LIAN-PIN LEE, JEN-SHIH		
IPC分类号	A61B8/00 A61B5/00 A61B6/00		
CPC分类号	A61B5/02042 A61M1/361 A61M1/342 A61M1/367 G01N29/024 G01N29/222 A61M1/3437 A61M1/3609 A61M2205/3306 A61M2205/3375 A61M2230/207 G01N2291/012 G01N2291/02466 G01N2291/02818 G01N2291/102 A61B8/06		
外部链接	Espacenet USPTO		

摘要(译)

一种评估血液的可压缩性，密度和血细胞比容的装置和方法，包括夹在血液流动的管道上的光学超声波探头。探头包括超声换能器，发光二极管和光电二极管的组合。将指示剂培养基在一个或多个时间点注射到受试者的血流中。超声波由换能器发射并由另一个换能器接收，并且新颖的信号处理单元和具有新颖计算方案的计算机处理超声信号以评估超声波在血流中传输时的相移。

